BioCentury
ARTICLE | Company News

Bayer's riociguat gets Priority Review

April 9, 2013 1:08 AM UTC

Bayer AG (Xetra:BAYN) said FDA accepted and granted Priority Review to an NDA for riociguat to treat pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic pulmonary hypertension ...